A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma Delta (γδ) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2

ADI-001 - Adicet Bio

Sattva S. Neelapu, MD1; Mehdi Hamadani, MD2; Don Stevens, MD3; Sandra M. Hayes, PhD4; Francesco Galimi, MD, PhD5; David B. Miklos, MD, PhD6

Nov 5, 2021